Melanoma & Skin Cancer

Here is your cheat sheet to all oncology therapeutic options that were cleared or rejected by the FDA in April 2026.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HER2+ breast cancer, pancreatic cancer, colorectal cancer, and melanoma.

iSCIB1+ has received fast track designation from the regulatory agency as a potential therapeutic options for patients with advanced melanoma.

The 5-year OS rate favored tebentafusp vs investigator’s choice of therapy in HLA-A*02:01–positive uveal melanoma.

Daniel Johnson, MD, discusses the use of TIL therapy in melanoma, including patient selection, sequencing, timing, and emerging applications beyond skin cancer.

The FDA granted priority review to an I-DXd BLA for extensive-stage small cell lung cancer, a sBLA for zenocutuzumab in NRG1+ cholangiocarcinoma has been submitted to the FDA, and more.

Frontline darovasertib plus crizotinib generated a PFS improvement vs treatment of investigator’s choice in HLA-A*02:01–negative metastatic uveal melanoma.

The FDA issued a CRL to RP1 plus nivolumab in advanced melanoma, accepted a NDA for the TLX101-Px imaging agent in glioma, and more.

The FDA issued a CRL to RP1 plus nivolumab for the management of advanced melanoma after progression on an anti–PD-1–containing regimen.

Tebentafusp use was associated with frequent dermatologic AEs, with desquamation and hypopigmentation observed in non-White patients in a real-world analysis.

Sensitivity analyses accounting for new primary melanoma did not diminish the RFS benefit favoring adjuvant pembrolizumab vs placebo in high-risk stage II melanoma.

Limited knowledge of long-term irAEs points to the need for more concentrated research regarding optimal postimmunotherapy toxicity management.

Disrupting liver-driven immune sink by depleting macrophages and preventing T-cell clearance restores responsiveness to immunotherapy in melanoma.

Mario Sznol, MD, discusses adjuvant vs neoadjuvant immunotherapy in melanoma and highlights emerging vaccines, cell therapies, and T-cell engagers.

Data from the phase 2 SWOG S1512 trial showed a high pCR and durable survival outcomes with neoadjuvant pembrolizumab in resectable desmoplastic melanoma.

Mario Sznol, MD, discusses how the field is balancing dual checkpoint blockade and novel combinations in melanoma, plus unmet needs and emerging strategies.

The FDA approves pembrolizumab regimen in select ovarian cancer, the agency clears Optune Pax for pancreatic cancer, and more this week.

An sNDA has been filed with the FDA for aminolevulinic acid topical gel plus RhodoLED red light lamps in superficial basal cell carcinoma.

Real-world data show over an 40% response rate for lifileucel TIL therapy, for previously treated advanced melanoma.

Only a proportion of patients with advanced melanoma proceeded to TIL therapy following referral in a real-world setting.

The American Cancer Society has released their annual Cancer Facts & Figures and Cancer Statistics reports.

Melphalan/HDS produced antitumor activity in metastatic uveal melanoma, including a consistent ORR across key subgroups.

SCIB1/iSCIB1+ plus ipilimumab and nivolumab displayed T-cell responses in treatment-naive, unresectable melanoma.

Jessica C. Hassel, MD, discusses the mechanism of action of the IO102-IO103 vaccine and the implications of its efficacy data in melanoma.

Here is your Q1 2026 preview spotlighting 5 FDA decisions to watch, including upcoming PDUFAs for tabelecleucel, pembrolizumab, and more.